Highest-materiality recent filing
Oscar Health Q1 net income $679M ($2.07 EPS) vs $275M ($0.92) YoY; revenue $4.65B
Revenue $4.65B, up 53% YoY from $3.05B; net income $679M ($2.07 EPS) vs $275M ($0.92 EPS) YoY.
Oscar Health reports record 3.4M members, FY2025 net loss $443M; guides FY2026 revenue $18.7-$19B
Full-year 2025 net loss $443.2M ($1.69 diluted EPS) vs prior-year net income $25.4M ($0.10 diluted EPS).
Oscar Health Q3 net loss $137.5M ($0.53 EPS); exchanges $187.5M notes for 23.3M shares
Q3 total revenue $2.99B (+23% YoY); net loss $137.5M vs $54.6M loss YoY; Adj EBITDA loss $101.5M vs $11.6M loss.
Oscar Health issues $410M of 2.25% convertible notes due 2030; net proceeds ~$395.8M
Notes carry 2.25% coupon, mature Sep 1, 2030; initial conversion price ~$24.82 per share.
Oscar Health prices $355M 2.25% convertible notes due 2030; uses proceeds for growth and AI
Upsized offering of $355M (from $350M); 2.25% interest, due September 1, 2030.
Oscar Health proposes $350M convertible notes due 2030; to fund AI, growth initiatives
$350M principal amount of convertible senior subordinated notes due 2030; underwriters option for additional $52.5M.
Oscar Health Q2 net loss $228.4M, MLR 91.1% vs 79.0% YoY; revenue up 29%
Total revenue: $2.86B, up 29% YoY from $2.22B on higher membership, partly offset by risk adjustment accrual.
Oscar Health expects Q2 operating loss ~$230M; cuts FY2025 guidance on higher ACA risk scores
Q2 expects loss from operations of ~$230M and net loss of ~$228M.
Oscar Health reports Q1 2025 revenue of $3.05B, net income $275M, and reaffirms full-year guidance
Total revenue rose 42% year-over-year to $3.046 billion for Q1 2025, driven by higher membership.
Total Revenue $9.2B (+56.5% YoY); Net income $25.4M ($0.10 diluted EPS) vs loss of $270.7M in 2023.
Oscar Health Q3 revenue $2.4B (+68% YoY); narrows loss; raises FY revenue guidance
Total revenue $2.4B, +68% YoY; net loss $54.6M ($0.22 EPS) improved $10.8M YoY.
Oscar Health Q2 net income $56.2M, rev $2.2B +46% YoY, raises FY guidance
Net income of $56.2M ($0.20 diluted EPS) vs. loss of $15.5M a year ago.
Oscar Health reports first-ever quarterly net income of $177.4M; revenue up 46% YoY
Q1 2024 net income of $177.4M ($0.62 diluted EPS) vs. net loss of $39.8M in Q1 2023.
Oscar Health posts FY2023 net loss $271M; 2024 adjusted EBITDA guidance positive $125M-$175M
FY2023 Direct and Assumed Policy Premiums $6.6B (-3% YoY); Premiums earned $5.7B (+47% YoY).
Oscar Health Q3 net loss narrows to $65.7M; raises 2023 EBITDA outlook; new +Oscar deal
Net loss of $65.7M vs $193.5M loss YoY; Adjusted EBITDA loss of $20.3M vs $159.8M loss YoY.
Net loss of $15.4M improved $96.7M YoY; Adjusted EBITDA $35.6M vs -$75.8M YoY.
Oscar Health Q1 net loss narrows to $39.6M; adjusted EBITDA turns positive at $51.1M
Premiums earned up 50% YoY to $1.4B; Direct & Assumed Policy Premiums $1.7B (+2% YoY).
Oscar Health appoints Mark Bertolini CEO; Schlosser moves to President of Technology
Mark Bertolini (ex-Aetna CEO) becomes CEO and board member effective April 3, 2023; Mario Schlosser transitions to President of Technology.
Oscar Health reports FY 2022 net loss $610M; guides 2023 to near breakeven adjusted EBITDA
Full-year 2022 premiums earned $3.9B, up 111% YoY; Direct & Assumed Policy Premiums $6.8B, up 99%.
Membership of 1,075,445 as of Sep 30, 2022, up 81% YoY; premiums earned $954M, up 116% YoY.
Oscar Health Q2 2022: revenue up 88% YoY to $995M, net loss widens to $112M; reaffirms FY22 outlook
Membership 1,036,720 (+84% YoY); Direct & Assumed Premiums $1.7B (+101%).
Oscar Health Q1 membership up 98% to 1.07M; net loss narrows to $77M
Direct and Assumed Policy Premiums $1.68B (+104% YoY); Premiums earned $955M (+159% YoY).
Mr. Schlosser’s transition from President of Technology and Chief Technology Officer of the Company to Co-Founder & Advisor to the CEO.
appointed Janet Liang as EVP and President of Oscar Insurance, effective February 24, 2025.
Steven Wolin resigned as EVP and Chief Operating Officer of the Company, effective as of February 5, 2025.
Alessandrea Quane, the Company’s EVP, Chief Insurance Officer, will cease serving in this role effective as of February 24, 2025 and her employment with the Company and Oscar Management Corporation (“OMC”) will terminate effective as of March 3, 2025.
Effective August 14, 2023, R. Scott Blackley will become the Company’s Chief Financial Officer (“CFO”).
Mr. Siddhartha Sankaran will remain CFO through that date.
On May 26, 2023, Oscar Health, Inc. (the “Company”) and Siddhartha Sankaran agreed that Mr. Sankaran will conclude his role as the Company’s Interim Chief Financial Officer as of August 31, 2023
Mark T. Bertolini will join the Company as Chief Executive Officer and a member of the Company’s Board of Directors
Co-founder Mario Schlosser will move into the role of President of Technology
On December 7, 2022, Charles E. Phillips, Jr. notified the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) of his decision to resign from the Board, effective as of December 31, 2022.
On December 6, 2022, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) increased the size of the Board from a total of eight directors to ten directors and appointed Ms. Laura Lang and Mr. Bill Gassen to the Board, effective as of December 7, 2022
On December 6, 2022, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) increased the size of the Board from a total of eight directors to ten directors and appointed Ms. Laura Lang and Mr. Bill Gassen to the Board, effective as of December 7, 2022
Max materiality 0.90 · Median 0.50 · Most common event earnings